

.

---

**From:** Piro, Peter (DPH)  
**Sent:** Wednesday, July 13, 2011 1:43 PM  
**To:** Salemi, Charles (DPH); Saunders, Della (DPH); Renczkowski, Daniel (DPH); Khan, Annie (DPH); O'Brien, Elisabeth (DPH); Corbett, Kate (DPH); Medina, Nicole (DPH); Lawler, Michael (DPH); Glazer, Lisa (DPH); Frasca, Daniela (DPH); Tran, Mai (DPH); Tan, Zhi (DPH)  
**Subject:** FW: MDPV

---

**From:** Nassif, Julianne (DPH)  
**Sent:** Wednesday, July 13, 2011 1:26 PM  
**To:** Piro, Peter (DPH)  
**Subject:** Re: MDPV

I would report the compounds with no legal interpretation. And leave it up to the da

---

**From:** Piro, Peter (DPH)  
**Sent:** Wednesday, July 13, 2011 01:22 PM  
**To:** Nassif, Julianne (DPH)  
**Subject:** MDPV

Hi Julie,

We possibly have methylenedioxy pyrovalerone (MDPV), one of the bath salts. DEA Diversion considers it an analog of MDEA (Sch 1). I have three questions.

1. How should we be reporting Federally Scheduled 1 Drugs that do not appear in Mass. Laws? i.e.- Benzylpiperazine
2. How should we report Schedule 1 analogs? i.e. MDPV
3. Is this addressed anywhere in our Controlled Substance Act? The Massachusetts Class E section only mentions prescription drugs other than those included in Classes A, B, C, D, and E subsection.

Thanks  
Peter